1. Scrip
  2. >>Business

Generate Biomedicines Picks First Targets To Test Its AI-Based Drug Discovery Revolution

Mutation-Resistant COVID-19 Therapy Is First Candidate

 
• By Andrew McConaghie

Built with an audacious goal to use AI to unlock the secrets of protein structure and function, Generate Biomedicines believes it is now on the cusp of a drug discovery revolution.

Flagship Pioneering
Generate Biomedicines was founded by Flagship Pioneering in 2018. • Source: Flagship Pioneering

On a mission to revolutionize drug discovery by generating novel biologic drugs based on new understanding of proteins, Generate Biomedicines has unveiled its first targets for its AI-based platform, and a mutation-resistant anti-COVID antibody is already in its crosshairs.

The Cambridge, MA-based company was set up in 2018 by venture capital firm Flagship Pioneering to tap into new computing power to learn the generalizable rules by which nature...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

More from Scrip

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.